SIREN : 822928214
GENI PHARMA is a French company founded 9 years ago, specialized in the sector Activités des sociétés holding. Based in ARLES (13200), this company of category PME shows in 2025 a net income positive of 130 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
| Net income | 129 906 € | 123 691 € | 172 047 € | 117 324 € | 145 177 € | 120 239 € | 42 059 € | 98 625 € | -12 555 € |
| EBITDA | -5 645 € | -6 037 € | -6 573 € | -6 751 € | -7 253 € | -7 642 € | -11 323 € | -7 472 € | -12 551 € |
| Net margin | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
In 2025, GENI PHARMA generates positive net income of 130 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
-5 645 €
-5 645 €
129 906 €
The debt ratio (= Financial debt / Equity x 100) stands at 56%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 58%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 4.8 years of cash flow to repay all financial debt. This ratio remains within usual banking standards.
56.132%
58.446%
4.824
In 2025, the debt ratio of GENI PHARMA (56.13) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of GENI PHARMA (58.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2025, the repayment capacity of GENI PHARMA (4.82) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 1.07. Coverage is just sufficient: any customer payment delay could create cash tensions.
1.074
-202.338
In 2025, the liquidity ratio of GENI PHARMA (1.07) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2025, the interest coverage of GENI PHARMA (-202.3x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 10 days. Favorable situation: supplier credit is longer than customer credit by 10 days.
0 €
0 j
10 j
0 j
Indicative estimate only : the number of comparable transactions in this sector is limited (20 transactions). This range of 51 803€ to 1 596 450€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 20 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare GENI PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of GENI PHARMA is not publicly disclosed (confidential accounts filed with INPI).
Yes, GENI PHARMA generated a net profit of 130 k€ in 2025.
The headquarters of GENI PHARMA is located in ARLES (13200), in the department Bouches-du-Rhone.
The tax return of GENI PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
GENI PHARMA operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.